Contrast medium induced nephropathy: New insights into prevention and risk management

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 2, 2009, Pages 166-180

  Vercellino, M ^a   Bezante, Gian Paolo ^a   Balbi, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Acetylcysteine; Ascorbic acid; Bicarbonate; Contrast media; Contrast nephropathy; Fenoldopam; Half saline; Hydration; Renal insufficiency; Risk score; Saline; Vasodilators

Indexed keywords

ACETRIZOIC ACID; ACETYLCYSTEINE; AMINOGLYCOSIDE DERIVATIVE; ANTIOXIDANT; ASCORBIC ACID; CAPTOPRIL; CONTRAST MEDIUM; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DIATRIZOATE; DIPYRIDAMOLE; FENOLDOPAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOBITRIDOL; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOTROLAN; IOVERSOL; IOXAGLIC ACID; METFORMIN; NONIONIC CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TACROLIMUS; VANCOMYCIN; VASODILATOR AGENT;

ANEMIA; ANTIHYPERTENSIVE THERAPY; AORTA BALLOON; CONTRAST INDUCED NEPHROPATHY; COUNTERPULSATION; DIABETES MELLITUS; DISEASE ASSOCIATION; EVENING DOSAGE; FLUID THERAPY; HEMODIALYSIS; HUMAN; HYPOTENSION; ISCHEMIA; KIDNEY FAILURE; KIDNEY INJURY; LACTIC ACIDOSIS; MORNING DOSAGE; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; KIDNEY DISEASE; RISK MANAGEMENT; STANDARD;

CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; PROGNOSIS; RISK FACTORS; RISK MANAGEMENT;

EID: 67650639287     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509787847083     Document Type: Review

References (181)

1. Bartels, E.D.; Brun, G.C.; Gammeltoft, A.; Gjorup, P. A. Acute anuria following intravenous pyelography in a patients with myelomatosis. Acta Med. Scand., 1954, 150, 297.
2. Briguori, C.; Tavano, D.; Colombo, A. Contrast agent associated nephrotoxicity. Prog. Cardiovasc. Dis., 2003, 45, 493.
3. Rubin, G.D.; Shiau. M.C.; Schmidt, A.J.; Logan, L.J.; Sofilos, J. Computed tomographic angiography: historical prospective and new state-of-the-art using multi detector-row helical computed tomography. J. Comput. Assist. Tomogr. Suppl., 1999, 23, S83.
4. Togni, M.; Balmer, F.; Pfiffner, D.; Maier, W.; Zeiher, AM.; Meier, B. Percutaneous coronary interventions in Europe 1992-2001. Eur. Heart J., 2004, 25, 1208.
5. Rotter, M.; Pfiffner, D.; Maier, W.; Zeiher, A.M.;Meier, B. Interventional cardiology in Europe 1999. Eur. Heart J., 2003, 24, 1164.
6. Parfrey, P.S.; Griffiths, S.M.; Barrett, B.J.; Paul, D.M.; Genge, M.; Withers, J.; Farid, N.; McManomon, P. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. N. Eng. J. Med., 1989, 320, 143.
7. Gleeson, T.G.; Bulugahapitiya, S. Contrast-induced nephropathy. Am. J. Roentgenol., 2004, 183, 1673.
8. US Renal Data System. USRDS 2001 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2001.
9. Xue, J.L.; Ma, J.Z.; Louis, T.A.; Collins, A.J. Forecast of the number of participants with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol., 2001, 12, 2753.
10. Rigalleau, V.; Lasseur, C.; Perlemoine, C.; Barthe, N.; Raffaitin, C.; Liu, C.; Chauveau, P.; Baillet-Blanco, L.; Beauvieux, M.C.; Combe, C.; Gin, H. Estimation of glomerular filtration rate in diabetic subjects. Cockroft formula or modification of diet in renal disease study equation? Diabetes Care, 2005, 28, 838.
11. Ritz, E.; Orth, S.R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med., 1999, 341, 1127.
12. Ritz, E.; Rychlik, I.; Wahl, P.; Michael, C. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimension. Am. J. Kidney. Dis., 1999, 34, 795.
13. Thomsen, H.S. Guidelines for contrast media from the European Society of Urogenital Radiology. Am. J. Roentgenol., 2003, 181, 1463.
14. McCullough, P.A.; Sandberg, K.R. Epidemiology of contrast-induced nephropathy. Rev. Cardiovasc. Med. Suppl., 2003, 4, S3.
15. Solomon, R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int., 2005, 68, 2256.
16. Stevens, M.A.; McCullough, P.A.; Tobin, K.J.; Speck J.P.; Westveer D.C.; Guido-Allen D.A.; Timmis G.C.; O'Neil W.W. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study prevention of radiocontrast induced nephropathy clinical evaluation. J. Am. Coll. Cardiol., 1999, 33, 403.
17. Guitterez, N.V.; Diaz, A.; Timmis, G.C.; O'Neil, W.W.; Stevens, M.A. Determinants of serum creatinine trajectory in acute contrast nephropathy. J. Interv. Cardiol., 2002, 15, 349.
18. Persson, P.B.; Hansell, P.; Liss, P.; Lagerqvist, B. Pathophysiology of contrast medium induced nephropathy. Kidney Int., 2005, 68, 14.
19. Thomsen, H.S.; Morcos, S.K. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br. J. Radiol., 2003, 76, 513.
20. Solomon, R. Radiocontrast-induced nephropathy. Semin. Nephrol., 1998, 18, 551.
21. Hardiek, K.; Katholi, R.E.; Ramkumar, V.; Deitrick, C. Proximal tubule cell response to radiographic contrast media. Am. J. Renal. Physiol., 2001, 280, F61.
22. Hizoh, I.; Strater, J.; Schick, C.S. Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: role of hypertonicity. Nephrol. Dial. Transplant., 1998, 13, 911.
23. Tepel, M.; Van der, G.M.; Schwarzfeld, C.; Laufer, U.; Liermann, D.; Zidek, W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med., 2000, 343, 180.
24. Diaz-Sandoval, L.J.; Kosowsky, B.D.; Losordo, D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am. J. Cardiol., 2002, 89, 356.
25. Briguori, C.; Manganelli, F.; Scarpato, P.; Elia, P.P.; Golia, B.; Riviezzo, G.; Lepore, S.; Librera, M.T.; Villari, B.; Colombo, A.; Ricciarelli, B. Acetylcysteine and contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol., 2002, 40, 298.
26. Shyu, K.G.; Cheng, J.J.; Kuan, P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol., 2002, 40, 1383.
27. Allaqaband, S.; Tumuluri, R.; Malik, A.M.; Gupta, A.; Volkert, P.; Shalev, Y.; Bajwa, T.K.; Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radio-contrast-induced nephropathy. Catheter. Cardiovasc. Interv., 2002, 57, 279.
28. Liss, P.; Nygren, A.; Erikson, U.; Ulfendahl, H.R. Injection of low and iso-osmolality contrast medium decreases oxygen tension in the renal medulla. Kidney Int., 1998, 53, 698.
29. McClennan, B.L.; Preston, M. Ionic and nonionic iodinated contrast media: evolution and strategies for use. Am. J. Roengtenol., 1990, 155, 225.
30. Morris, T.W. X-ray contrast media: where are we now and where are we going? Radiology, 1993, 188, 11.
31. Eloy, R.; Corot, C.; Belleville, J. Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility. Clin. Mater., 1991, 7, 89.
32. Katzberg, R.W. State of the Art. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology, 1997, 204, 297.
33. Stacul, F. Current iodinated contrast media. Eur. Radiol., 2001, 11, 690.
34. Almén, T. Visipaque: a step forward - a historical review. Acta Radiol. Suppl., 1995, 36, S2.
35. Spataro, R.F. Newer contrast agents for urography. Radiol. Clin. North. Am., 1984, 22, 365.
36. Sovak, M. The Harry W. Fischer lecture: contrast media - a meandering look. Acad. Radiol., 1996, 3, S241.
37. Idée, J.M.; Jachman, I.; Port, M. Iodinated contrast media: from non-specific to blood-pool agents. Top. Curr. Chem., 2002, 222, 153.
38. Ueda, J. Effect of contrast media on single nephron functions. Thesis. Uppsala University, Uppsala, Sweden, 1991.
39. Liss, P. Effects of contrast media in renal microcirculation and oxygen tension: an experimental study in the rat. Thesis. Uppsala University, Uppsala, Sweden, 1996.
40. Voeltz, M.D.; Nelson. M.A.; McDaniel, M.C.; Manoukian, S.V. The important properties of contrast media: focus on viscosity. J. Invasive. Cardiol., 2007, 19(3), 1.
41. Dobrota, M.; Powell, C.J.; Holtz, E.; Wallen, A.; Vik, H. Biochemical and morphological effects of contrast media on the kidney. Acta Radiol., 1995, 36, 196.
42. Petta, M.; Raynal, I.; Bourrinet, P. Nonionic compact dimers: a new generation of isomolar iodinated contrast media with low viscosity. Acad. Radiol., 1998, 5, 41.
43. Lasser, E.C.; Lyon, S.G.; Berry, C.C. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration. Radiology, 1997, 203, 605.
44. Rich, M.W.; Crecelius, C.A. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch. Intern. Med., 1990, 150, 1237.
45. Rihal, C.S.; Textor, S.C.; Grill, D.E.; Berger, P.B.; Ting, H.H.; Singh, M.; Bell, M.R.; Barsness, G.W.; Mathew, V.; Garratt, K.N.; Holmes, D.R. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation, 2002, 105, 2259.
46. McCullough, P.A.; Wolyn, R.; Rocher, L.L.; Levin, R.N.; O'Neil, W.W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am. J. Med., 1997, 103, 368.
47. Cockcroft, D.W.; Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron, 1976, 16, 31.
48. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med., 1999, 130, 461.
49. Nikolsky, E.; Mehran, R.; Turcot, D.; Aymong, E; Mintz, G.; Lasic, Z.; Lansky, A.; Tsounias, E.; Moses, J.; Stone, G. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am. J. Cardiol., 2004, 94, 300.
50. Kurnik, B.R.; Allgren, R.L.; Genter, F.C.; Solomon, R.J.; Bates, E.R.; Weisberg, L.S. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am. J. Kidney Dis., 1998, 31, 674.
51. Lautin, E.M.; Freeman, N.J.; Schoenfeld, A.H.; Bakal, C.W.; Haramati, N.; Friedman, A.C.; Lautin, J.L.; Braha, S. Radio-contrast-associated renal dysfunction: incidence and risk factors. Am. J. Roentgenol., 1991, 157, 49.
52. Diaz-Sandoval, L.J.; Kosowsky, B.D.; Losordo, D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am. J. Cardiol., 2002, 89, 356.
53. Rosovsky, M.A.; Rusinek, H.; Berenstein, A.; Basak, S.; Setton, A.; Nelson, P.K. High-dose administration of nonionic contrast media: a retrospective review. Radiology, 1996, 200, 119.
54. Kahn, J.K.; Rutherford, B.D.; McConahay, D.R.; Johnson, W.L.; Giorgi, L.V.; Hartzler, G.O. High-dose contrast agent administration during complex coronary angioplasty. Am. Heart J., 1990, 120, 533.
55. Manske, C.L.; Sprafka, J.M.; Strony, J.T.; Wang, Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am. J. Med., 1990, 89, 615.
56. Vlietstra, R.E.; Nunn, C.M.; Narvarte, J.; Browne, K.F. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am. Heart J., 1996, 132, 1049.
57. Nikolsky, E.; Mehran, R.; Lasic, Z.; Mintz, G.S.; Lansky, A.J.; Na, Y. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int., 2005, 67, 706.
58. Dangas, G.; Iakovou, I.; Nikolsky, E.; Aymong, E.D.; Mintz, G.S. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am. J. Cardiol., 2005, 95, 13.
59. Katholi, R.E.; Taylor, G.J.; Woods, W.T.; Womack, K.A.; Katholi, C.R.; McCann, W.P.; Moses, H.W.; Dove, J.T.; Mikell, F.L.; Woodruff, R.C. Nephrotoxicity of nonionic low-osmolarity versus ionic high-osmolarity contrast media: a prospective double-blind randomized comparison in human beings. Radiology, 1993, 186, 183.
60. Harris, K.G.; Smith, T.P.; Cragg, A.H.; Lemke, J.H. Nephrotoxicity from contrast material in renal insufficiency: ionic versus nonionic agents. Radiology, 1991, 179, 849.
61. Barrett, B.J.; Carlisle, E.J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolarity iodinated contrast media. Radiology, 1993, 188, 171.
62. Aspelin, P.; Aubry, P.; Fransson, S.G.; Strasser, R.; Willenbrock, R. Nephrotoxicity in high-risk patients study of iso-osmolar and low-osmolar non-ionic contrast media study investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N. Engl. J. Med., 2003, 348, 491.
63. Dzgoeva, F.U.; Milovanov, I.; Kutyrina, I.M. Acute kidney failure related to the use of X-ray contrast agents and indomethacin: the risk factors and mechanisms of its development. Ter. Arkh., 1995, 67, 36.
64. Carvallo, A.; Rakowski, T.A.; Argy, W.P., Jr.; Schreiner, G.E. Acute renal failure following drip infusion pyelography. Am. J. Med., 1978, 65, 38.
65. Segal, R.; Lubart, E.; Leibovitz, A.; Berkovitch, M.; Habot, B.; Yaron, M.; Caspi, D. Early and late effects of low-dose aspirin on renal function in elderly patients. Am. J. Med., 2003, 115, 462.
66. Swan, S.K.; Rudy, D.W.; Lasseter, K.C.; Ryan, C.F.; Buechel, K.L.; Lambrecht, L.J.; Pinto, M.B.; Dilzer, S.C.; Obrda, O.; Sundblad, K.J. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann. Intern. Med., 2000, 133, 1.
67. Palmer, B.F. Renal dysfunction complicating the treatment of hypertension. N. Engl. J. Med., 2002, 347, 1256.
68. Toprak, O.; Cirit, M.; Bayata, S.; Yesil, M.; Aslan, L.S. The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu. Kardiyol. Derg., 2003, 3, 98.
69. Gupta, R.K.; Kapoor, A.; Tewari, S.; Sinha, N.; Sharma, R.K. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J., 1999, 51, 521.
70. Katholi, R.E.; Taylor, G.J.; McCann, W.P.; Woods, W.T.; Womack, K.A.; McCoy, C.D. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology, 1995, 195, 17.
71. Arend, L.J.; Bakris, G.L.; Burnett, J.C.J.; Megerian, C.; Spielman, W.S. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J. Lab. Clin. Med., 1987, 110, 406.
72. Moore, R.D.; Smith, C.R.; Lipsky, J.; Mellits, E.D.; Lietman, P.S. Risk factors for nephrotoxicity in patients treated with aminoglycosides. J. Ann. Intern. Med., 1984, 100, 352.
73. Ali, M.Z.; Goetz, M.B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis., 1997, 24, 796.
74. Goetz, M.B.; Sayers, J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J. Antimicrob. Chemother., 1993, 32, 325.
75. Paiva, H.; Thelen, K.M.; Van Coster, R.; Smet, J.; De Paepe, B.; Mattila, K.M.; Laasko, J. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther., 2005, 78, 60.
76. Al Shohaib, S. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am. J. Nephrol., 2000, 20, 212.
77. Moro. H.; Tsukada, H.; Tanuma, A. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS, 2004, 18, 687.
78. Khanal, S.; Attallah, N.; Smith, D.E.; Kline-Rogers, E.; Share, D.; O'Donnell, M.; Moscucci, M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am. J. Med., 2005, 118, 843.
79. Attallah, N.; Yassine, L.; Musial, J.; Yee, J.; Fisher, K. The potential role of statins in contrast nephropathy. Clin. Nephrol., 2004, 62, 273.
80. Gueler, F.; Rong, S.; Park, J.K.; Fiebeler, A.; Menne, J.; Elger, M.; Mueller, D.N.; Hampich, F.; Dechend, R. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J. Am. Soc. Nephrol., 2002, 13, 2288.
81. Mehran, R.; Aymong, E.D.; Nikolsky, E.; Lasic, Z. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J. Am. Coll. Cardiol., 2004, 44, 1393.
82. Gruberg, L.; Mintz, G.S.; Mehran, R.; Gangas, G.; Lansky, A.J.; Kent, K.M.; Pichard, A.D.; Satler, L.F.; Leon, M.B. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J. Am. Coll. Cardiol., 2000, 36, 1542.
83. Bartholomew, B.; Harjai, K.J.; Dukkipati, S.; Boura, J.A.; Yerkey, M.W. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am. J. Cardiol., 2004, 93, 1515.
84. Marenzi, G.; Lauri, G.; Assanelli, E.; Campodonico, J.; De Metrio, M.; Marana, I.; Grazi, M.; Veglia, F.; Bartorelli, A.L. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol., 2004, 44, 1780.
85. Levy, E.; Viscoli, C.M.; Horwitz, R.I. The effect of acute renal failure on mortality. A cohort analysis. JAMA, 1996, 275, 1489.
86. Lindsay, J.; Canos, D.A.; Apple, S.; Pinnow, E.E.; Aggrey, G.K.; Pichard, A.D. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise in creatine kinase-MB versus rise in serum creatinine. Am. J. Cardiol., 2004, 94, 786.
87. Solomon, R.; Werner, C.; Mann, D.; D'Elia, E.; Silva, P. Effects of saline, mannitol, and furosemide on acute decrease in renal function induced by radiocontrast agents. N. Engl. J. Med., 1994, 331, 1416.
88. Taylor, A.J.; Hotchkiss, D.; Morse, R.W.; McCabe, J. Preparation for angiography in renal dysfunction. A randomized trial of inpatient versus outpatient hydration protocols for cardiac catheterization in mild to moderate renal dysfunction. Chest, 1998, 114, 1570.
89. Erley, C.M. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol. Dial. Transplant, 1999, 14, 1064.
90. Mueller, C.; Buerkle, G.; Buettner, H.J.; Petersen, J. Prevention of contrast media-associated nephropathy: randomized comparison of two hydration regimens in 1620 patients undergoing coronary angioplasty. Arch. Intern. Med., 2002, 162, 329.
91. Trivedi, H.S.; Moore, H.; Nasr, S.; Aggarwal, K.; Agrawal, A.; Goel, P.; Hewett, J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephropathy. Nephron. Clin. Pract., 2003, 93, c29.
92. Bader, B.D.; Berger, E.D.; Heede, M.B.; Silberbaur, I.; Duda, S.; Rislert, T.; Erley, C.M. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin. Nephrol., 2004, 62, 1.
93. Holt. S. Radiocontrast media-induced renal injury - saline is effective in prevention. Nephron. Clin. Pract., 2003, 93, c5.
94. Anto, H.R.; Chou, S.Y.; Porush, J.G.; Shapiro, W.B. Infusion intravenous pyelography and renal function. Effect of hypertonic mannitol in patients with chronic renal insufficiency. Arch. Intern. Med., 1981, 141, 1652.
95. Eisenberg, R.L.; Blank, W.O.; Hedgock, M.W. Renal failure after major angiography can be avoideed with hydration. Am. J. Radiol., 1981, 136, 859.
96. Kerstein, M.D.; Puyau, F.A. Value of preangiography hydration. Surgery, 1984, 96, 919.
97. Krasuski, R.A.; Beard, B.M.; Geoghagan, J.D.; Thompson, C.M.; Guidera, S.A. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J. Invasive Cardiol., 2003, 15, 699.
98. Mueller, C.; Buerkle, G.; Perruchoud, A.P.; Buettner, H.J. Female sex and the risk of contrast nephropathy after percutaneous coronary intervention. Can. J. Cardiol., 2004, 20, 505.
99. Merten, G.J.; Burgess, W.P.; Gray, L.V.; Holleman, J.H.; Roush, T.S.; Kowalchuk, G.J.; Bersin, R.M.; Van Moore A.; Simonton, 3rd, C.A.; Rittase, R.A. Prevention of contrast-induced nephropathy with sodium bicarbonate. A randomized controlled trial. JAMA, 2004, 291, 2328.
100. Nash, K.; Hafeez, A.; Hou, S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis., 2002, 39, 930.
101. Katzberg, R.W.; Haller, C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int. Suppl., 2006, 100, S3.
102. Freeman, R.; O'Donnell, M.; Share, D.; Meengs, W.L.; Kline-Rogers, E.; Clark, V.L.; De Franco, A.C.; Eagle, K.A.; McGinnity, J.G.; Patel, K.; Maxwell-Edward, A.; Bondie, D.; Moscucci, M. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am. J. Cardiol., 2002, 90, 1068.
103. Cigarroa, R.; Lange, R.A.; Williams, R.H.; Hillis, L.D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am. J. Med., 1989, 86, 649.
104. Becker, C.; Reiser, M.F. Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest. Radiol., 2005, 40, 672.
105. Carraro, M.; Malalan, F.; Antonione, R.; Stacul, F.; Cova, M.; Petz, S. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur. Radiol., 1998, 8, 144.
106. Jakobsen, J.; Berg, K.J.; Brodahl, U.; Laake, B.; Moxness, A. Renal effects of nonionic contrast media after cardioangiography. Acad. Radiol., 1994, 35, 191.
107. Campbell, D.; Flemming, B.K.; Mason, W.F.; Jackson, S.A. A comparative study of the nephrotoxicity of iohexol, iopamidol, and ioxaglate in peripheral angiography. J. Can. Assoc. Radiol., 1990, 41, 133.
108. Rudnick, M.; Goldfarb, S.; Wexler, L.; Berns, J.S.; Cohen, R.M. Nephropathy of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int., 1995, 47, 254.
109. Chalmers, N.; Jacksonn, R.W. Comparison of iodixanol an iohexol in renal impairment. Br. J. Radiol., 1999, 72, 701.
110. Jo, S.H.; Youn, T.J.; Park, J.S.; Koo, B.K.; Hang H.J. Iodixanol is less nephrotoxic than ioxaglate in patients with renal insufficiency after coronary angiography. J. Am. Coll. Cardiol. Suppl., 2005, 45, A31.
111. Solomon, R. The role of osmolality in the incidence of contrast induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int., 2005, 68, 2256.
112. Briguori, C.; Colombo, A.; Airoldi, F.; Morici, N.; Sangiorgi, G.M.; Violante, A.; Focaccio, A. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int., 2005, 68, 2250.
113. Barrett, B.J.; Katzberg, R.W.; Thomsen, H.S.; Chen, N.; Sahani, D.; Soules, G.; Heiken, J.P.; Lepanto, L.; Ni, Z-hui.; Nelson, R. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computer tomography: a double-blind comparison of iodixanol and iopamidol. Invest. Radiol., 2006, 41, 815.
114. DiMari, J.; Megyesi, J.; Udvarhelyi, N.; Price, P.; Davis, R.; Safirstein, R. N-acetylcysteine ameliorates ischemic renal failure. Am. J. Physiol., 1997, 272, F292.
115. Heyman, S.N.; Goldfarb, M.; Shina, A.; Karmeli F.; Rosen S. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int., 2003, 63, 634.
116. Tariq, M.; Morais, C.; Sobki, A.; Sulaiman, M.; Khader, A. N-acetylcysteine attenuates cyclosporin-Induced nephrotoxicity in rats. Nephrol. Dial. Transplant., 1999, 14, 923.
117. Efrati, S.; Dishy, V.; Averbukh, M.; Blatt, A.; Krakover, R.; Weisgarten. J.; Morrow, J.; Stein, M.; Golik, A. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int., 2003, 64, 2182.
118. Kay, J.; Chow, W.H.; Chan, T.M.; Lo, S.K.; Know, O.H.; Yip, A.; Fan, K.; Lee, C.H.; Lam, W.F. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA, 2003, 289, 553.
119. Durham, J.D.; Caputo, C.; Dokko, J.; Zahrakis, T.; Pahlavan, M.; Keltz, J.; Dutka, P.; Marzo, K. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int., 2002, 62, 2202.
120. Webb, J.G.; Pate, G.E.; Humphries, K.H.; Buller, C.E.; Shalansky, S.; Al Shamari, A. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am. Heart. J., 2004, 148, 422.
121. Boccalandro, F.; Amhad, M.; Smalling, R.W.; Sdringola, S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter. Cardiovasc. Interv., 2003, 58, 336.
122. Goldenberg, I.; Shechter, M.; Matetzky, S.; Jonas, M.; Adam, M.; Hanna, P.; Elian, D.; Agranat, O.; Schwammenthal, E.; Guetta, V. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur. Heart J., 2004, 25, 212.
123. Oldemeyer, J.B.; Biddle, W.P.; Wurdeman, R.L.; Mooss, A.N.; Cichowski, E.; Hillman, D.E. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am. Heart J., 2003, 146, E23.
124. Briguori, C.; Colombo, A.; Violante, A.; Balestreri, P.; Manganelli, F.; Elia, P.P.; Golia, B.; Lepore, S.; Riviezzo, G.; Scarpato, P.; Focaccio, A.; Librera, M.; Bonizzoni, E.; Ricciardelli, B. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur. Heart J., 2004, 25, 206.
125. Birck, R.; Krzossok, S.; Markowetz, F.; Schulle, P.; Van der Woude, F.J.; Brau, C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet, 2003, 362, 598.
126. Alonso, A.; Lau, J.; Jaber, B.L.; Weintraub, A.; Sarnak, M.J. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am. J. Kidney Dis., 2004, 43, 1.
127. Pannu, N.; Manns, B.; Lee, H.; Tonelli, M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int., 2004, 65, 1366.
128. Kshirsagar, A.V.; Poole, C.; Mottl, A.; Shoham, D.; Franceschini, N.; Tudor, G.; Agrawal, M. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J. Am. Soc. Nephrol., 2004, 15, 761.
129. Isenbarger, D.W.; Kent, S.M.; O'Malley, P.G. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am. J. Cardiol., 2003, 92, 1454.
130. Nallamothu, B.; Shojania, K.G.; Saint, S.; Hofer, T.P.; Humes, H.D.; Moscucci, M.; Bates, E.R. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am. J. Med., 2004, 117, 938.
131. Duong, M.H.; Mackanzie, T.A.; Malenka, D.J. N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast induced nephropathy: comprehensive meta-analysis. Catheter. Cardiovasc. Interv., 2005, 64, 471.
132. Marenzi, G.; Assanelli, E.; Marana, I.; Lauri, G.; Campodonico, J.; Grazi, M.; De Metrio, M.; Galli, S.; Fabbiocchi, F.; Montorsi, P.; Veglia, F.; Bartorelli, A.L. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N. Engl. J. Med., 2006, 354 (26), 2773.
133. Spargias, K.; Alexopoulos, E.; Kyrzopoulos, S.; Iacovis, P.; Greenwood, D.C.; Manginas, A.; Voudris, V.; Pavlides, G.; Buller, C.B.; Kremastinos, D.; Cokkinos, D.V. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation, 2004, 110, 2837.
134. Briguori, C.; Airoldi, F.; D'Andrea, D.; Bonizzoni, E.; Morici, N.; Focaccio, A.; Michev, I.; Montorfano, M.; Carlino, M.; Cosgrave, J.; Ricciardelli, B.; Colombo, A. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation, 2007, 115(10), 1211.
135. Neumayer, H.H.; Junge, W.; Kufner, A.; Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomized clinical trial. Nephrol. Dial. Transplant., 1989, 4, 1030.
136. Carraro, M.; Mancini, W.; Artero, M.; Stacul, F.; Grotto, M.; Faccini, L. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol. Dial. Transplant., 1996, 11, 444.
137. Spangberg-Viklund, B.; Berglund, J.; Nikonoff, T.; Nyberg, P.; Skaut, T.; Larsson, R. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand. J. Urol. Nephrol., 1996, 30, 63.
138. Arici. M.; Usalan, C.; Altun, B.; Erdem, Y.; Yasavul, U.; Turgan, C.; Kes, S.; Caǧlar, Ş. Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. Int. J. Urol. Nephrol., 2003, 35, 255.
139. Russo, D.; Minatolo, R.; Cianciaruso, B.; Memoli, B.; Conte, G.; De Nicola, L. J. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. Am. Soc. Nephrol., 1995, 6, 1451.
140. Khoury, Z.; Schlicht, J.R.; Como, J.; Karschener, J.K.; Shapiro, A.P.; Mook, W.J. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy, 1999, 15, 59.
141. Pourrat, J.P.; Douste-Blazy, P. Renal side effects of nifedipine. Clin. Cardiol., 1984, 7, 29.
142. Cacoub, P.; Deray, G.; Baumelou, A.; Jacobs, C. No evidence for protective effects of nifedipine against radiocontrast induced acute renal failure. Clin. Nephrol., 1988, 29, 215.
143. Russo, D.; Testa, A.; Della Volpe, L.; Sasone, G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron, 1990, 55, 254.
144. Weisberg, L.S.; Kurnik, P.B.; Kurnik, B.R. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren. Fail., 1993, 15, 61.
145. Hans, B.; Hans, S.S.; Mittal, V.K.; Khan, T.A.; Patel, N.; Dahn, M.S. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. Radiology, 1990, 176, 651.
146. Hall, K.A.; Wong, R.W.; Hunter, G.C.; Camazine, B.M.; Rappaport, W.A.; Smyth, S.H.; Bull, D.A.; McIntyre, K.E.; Bernhard, V.M.; Misiorowski, R.L. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J. Surg. Res., 1992, 53, 317.
147. Kapoor, A.; Sinha, N.; Sharma, R.K.; Shrivastava, S.; Radhakrishnan, S.; Goel, P.K.; Bajaj, R. Use of dopamine in prevention of contrast induced acute renal failure. A randomized study. Int. J. Cardiol., 1996, 53, 233.
148. Hans, S.S.; Hans, B.A.; Dhillon, R.; Dmuchowski, C.; Glover, J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am. Surg., 1998, 64, 432.
149. Gare, M.; Haviv, Y.S.; Ben-Yehuda, A.; Rubinger, D.; Bdolah-Abram, T.; Fuchs, S.; Gat, O.; Popovtzer, M.M.; Gotsman, M.S.; Mosseri, M. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J. Am. Coll. Cardiol., 1999, 34, 1682.
150. Mathur, V.; Swan, S.; Lambrecht, L.; Anjum, S.; Fellman, J.; MCGuire, D.; Epstein, M.; Luther, R. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamic in normotensive subjects. Crit. Care. Med., 1999, 27, 1832.
151. Bakris, G.; Lass, N.A.; Glock, D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int., 1999, 56, 206.
152. Kini, A.S.; Mitre, C.A.; Kamran, M.; Suleman, J.; Kim, M.; Duffy, M.E.; Marmur, J.D.; Sharma, S.K. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am. J. Cardiol., 2002, 89, 999.
153. Madyoon, H.; Croushore, L.; Weaver, D.; Mathur, V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cathet. Cardiovasc. Interv., 2001, 53, 341.
154. Chamsuddin, A.A.; Kpwalik, K.J.; Bjarnason, H. Using a dopamine type 1a receptor agonist in high-risk patients to ameliorate contrast associated nephropathy. Am. J. Roentgenol., 2002, 179, 591.
155. Tumlin, J.A.; Wang, A.; Murray, P.T.; Mathur, V.S. Fenodopam mesylate blocks reduction in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am. Heart J., 2002, 143, 894.
156. Stone, G.W.; McCullough, P.A.; Tumlin, J.A.; Lepor, N.E.; Madyoon, H.; Murray, P.; Wang, A.; Chu, A.; Schare, G.L.; Stevens, M.; Wilensky, R.; O'Neil, W. Fenoldopam mesylate for the prevention of contrast-induced nephrotoxicity. JAMA, 2003, 290, 2284.
157. Briguori, C.; Colombo, A.; Airoldi, F.; Violante, A.; Castelli, A.; Balestrerieri, P.; Elia, P.P.; Golia, B.; Lepore, S.; Riviezzo, G.; Scarpato, P.; Librera, M.; Focaccio, A.; Ricciarelli, B. N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol., 2004, 44, 762.
158. Gandhi, M.R.; Brown, P.; Romanowski, C.A.; Morcos, S.K.; Campbell, S.; El Nahas, A.M.; Gray, T.A.J. The use of theophylline, an adenosine antagonist, in the prevention of contrast media induced nephropathy. Br. J. Radiol., 1992, 65(777), 838.
159. Erley, C.M.; Duda, S.H.; Schlepckow, S.; Koehler, J.; Huppert, P.E.; Strohmaier, W.L.; Bohle, A. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int., 1994, 45, 1425.
160. Kolonko, A.; Wiecek, A.; Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J. Nephrol., 1998, 11, 151.
161. Abizaid, A.; Clark, C.E.; Mintz, G.S.; Dosa, S.; Popma, J.J.; Pichard, A.D. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am. J. Cardiol., 1999, 83, 260.
162. Erley, C.M.; Duda, S.H.; Rehfuss, D. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol. Dial. Transplant., 1999, 14, 1146.
163. Huber, W.; Jeschke, B.; Page, M.; Weiss, W.; Salmhofer,H.; Schweigart, U.; Ilgmann, K. Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intens. Care. Med., 2001, 27, 1200.
164. Shammas, N.W.; Kapalis, M.J.; Harris, M. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J. Invas. Cardiol., 2001, 13, 738.
165. Huber, W.; Ilgmann, K.; Page, M. Effect of theophylline on contrast material-Induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology, 2002, 223, 772.
166. Wang, A.; Holcslaw, T.; Bashore, T.M.; Freed, M.I.; Miller, D.; Rudnick, M.R.; Szerlip, H.; Thames, M.D. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int., 2000, 57, 1675.
167. Koch, J.A.; Plum, J.; Grabensee, B.; Modder, U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol. Dial. Transplant., 2000, 15, 43.
168. Gurkowski, L.; MacDougall, M.; Wiegmann, T. Effects of misoprostol on contrast-induced renal dysfunction. Am. J. Ther., 1995, 2, 837.
169. Miller, H.I.; Dascalu, A.; Rassin, T.A.; Wollman, Y.; Chernichowsky, T.; Iaina, A. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am. J. Nephrol., 2003, 23, 91.
170. Ueda, J.; Furukawa, T.; Higashino, K.; Takahashi, S.; Araki, Y.; Sakaguchi, K. Elimination of iomeprol by hemodialysis. Eur. J. Radiol., 1996, 23, 197.
171. Furukawa, T.; Ueda, J.; Takahashi, S.; Sakaguchi, K. Elimination of low-osmolality contrast media by hemodialysis. Acta. Radiol., 1996, 37, 966.
172. Waaler, A.; Svaland, M.; Fauchald, P.; Jakobsen, J.A.; Kolmannskog, F.; Berg, K.J. Elimination of iohexol, a low osmolar non ionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron, 1990, 56, 81.
173. Frank, H.; Werner, D.; Lorusso, V.; Klinghammer, L.; Daniel, W.G.; Kunzendorf, U.; Ludwig, J. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced-nephropathy in chronic renal failure. Clin. Nephrol., 2003, 60(3), 176.
174. Lehnert, T.; Keller, E.; Gondolf, K.; Schaffner, T.; Pavenstadt, H.; Schollmeyer, P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol. Dial. Transplant., 1998, 13, 358.
175. Sterner. G.; Frennby, B.; Kurkus, J.; Nyman, U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand. J. Urol. Nephrol., 2000, 34, 323.
176. Vogt, B.; Ferrari, P.; Schonholzer, C.; Marti, H.P.; Mohaupt, M.; Wiederkehr, M.; Cereghetti, C.; Serra, A.; Huynh-Do, U.; Uehlinger, D.; Frey, F.J. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am. J. Med., 2001, 111, 692.
177. Marenzi, G.; Marana, I.; Lauri, G.; Assanelli, E.; Grazi, M.; Campodonico, J.; Trabattoni, D. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N. Engl. J. Med., 2003, 349, 1333.
178. Marenzi, G.; Lauri, G.; Campodonico, J.; Marana, I.; Assanelli, E.; De Metrio, M.; Grazi, M.; Veglia, F.; Fabbiocchi, F.; Montorsi, P. Comparison of two hemofiltration protocols for prevention of contrast induced nephropathy in high-risk patients. Am. J. Med., 2006, 119, 155.
179. Solomon, R.; Deray, G. Consensus Panel for CIN. Kidney. Int. Suppl., 2006, 100, S51.
180. Thomsen, H.S. Imaging patients with chronic kidney disease: CIN or NSF? Radiol. Med., 2007, 112(5), 621.
181. Pannu, N.; Wiebe, N.; Tonelli, M. Prophylaxis strategies for contrast-induced nephropathy. JAMA, 2006, 295, 2765.